ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Palivizumab

Also written as “Palivizumab 15 mg/kg”, “Lyophilized Palivizumab” and “Liquid Palivizumab”.

Its studies are mostly in Respiratory Syncytial Virus Infections · Bronchopulmonary Dysplasia · Bronchiolitis, led by 5 companies.

Drug pagePalivizumab: every studyMany companies study it; this page follows only the 9 they lead. All 10 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 3, 20059 company-led studies, 1 open or runningNext primary completion: Feb 28, 2027

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca41 open or runningphase 4since Oct 3, 2005Oct 3, 2005Feb 28, 2027NCT06851806
AbbVieits history only20 open or runningphase 3since Sep 12, 2011Sep 12, 2011none ahead
Abbottits history only10 open or runningphase 3since Nov 2, 2009Nov 2, 2009none ahead
Fresenius Kabiits history only10 open or runningphase 1since Jul 24, 2020Jul 24, 2020none ahead
Hamad Medicalits history only10 open or runningphase 3since May 10, 2015May 10, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 3, 2005First study: phase 4 study in Chronic Lung DiseaseFirst studyNCT00233064 · 417 enrolled · United States
  2. Oct 14, 2005Phase 2 study in -Unhealthy Children With a History of PrematurityNCT00240929 · 150 enrolled · United States
  3. Apr 18, 2006Phase 2 study in Respiratory Syncytial Virus InfectionsNCT00316264 · 260 enrolled · Australia, Chile, New Zealand
  4. Feb 10, 2025No phase study in Respiratory Syncytial Virus (RSV)NCT06851806 · 21 enrolled · India

Ahead

  1. Feb 28, 2027Primary completion: no phase study in Respiratory Syncytial Virus (RSV)NCT06851806

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Fusion glycoprotein F0 inhibitor”ChEMBL 37, by rule

Studies

All 4 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06851806Respiratory Syncytial Virus (RSV) · India–Active, not recruitingFeb 28, 202721
NCT00316264Respiratory Syncytial Virus Infections · Australia, Chile, New Zealand2CompletedFeb 2007260
NCT00240929-Unhealthy Children With a History of Prematurity · United States2Completed150
NCT00233064Chronic Lung Disease · United States4CompletedOct 2007417

How it is read

Names in the registry

  • “Palivizumab”, 4 entries
  • “Palivizumab 15 mg/kg”, 1 entry
  • “Lyophilized Palivizumab”, 1 entry
  • “Liquid Palivizumab”, 1 entry
  • “Motavizumab, palivizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.